4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Xenetic Biosciences, Inc. (XBIO) operates in the Biotechnology industry and is headquartered in Framingham, United States with about 2 employees. Its market capitalization is roughly $6 million. In the fiscal year ended 2025-12-31, XBIO reported $3M in revenue and ($3M) in net income.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers.
Interactive charts & full statements → Open the XBIO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $3M | $2M | $2M | $2M | — |
| Operating Income (EBIT) | ($3M) | ($4M) | ($4M) | ($7M) | — |
| Net Income | ($3M) | ($4M) | ($4M) | ($7M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $1M | $1M | $1M | $1M |
| Operating Income (EBIT) | ($0M) | ($1M) | ($0M) | ($1M) | ($1M) |
| Net Income | ($0M) | ($1M) | ($0M) | ($1M) | ($1M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $8M | $7M | $11M | $15M | — |
| Total Liabilities | $1M | $1M | $1M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XBIO viewer.
About TickerBase · Data methodology & sources